The process for the detection of monoclonal gammopathies (MGs) is highly complex. To obtain an accurate diagnosis, diagnostic data must be compiled from several areas of the laboratory (eg, total protein, immunoglobulin levels, gel or capillary electrophoreses patterns).
A primary goal of this guideline would be evidence-based recommendations for the laboratory detection and initial diagnosis of MGs. The scope includes testing modalities in peripheral blood and urine, and excludes testing on bone marrow. The scope will also include the reinforcement of the International Myeloma Working Group “Criteria for Diagnosis of Multiple Myeloma” for testing and reporting.
- What specimens are useful to detect MGs?
- What are the appropriate tests needed to accurately detect and quantify MGs?
- What information should be included in the laboratory order? And which laboratory tests are best used in which patients? What appropriate ancillary testing should be recommended?
American Association for Clinical Chemistry
American Society for Clinical Pathology
American Society of Hematology
International Myeloma Working Group
David Keren, MD, FCAP, Co-chair
M. Qasim Ansari, MD, FCAP, Co-chair
Gregary Bocsi, DO, FCAP
Joan Etzell, MD, FCAP
James Faix, MD, FCAP
Shaji Kumar, MD
Brea Lipe, MD
Christopher McCudden, PhD
Roberta Montgomery, MLS(ASCP)cmSI(ASCP)
David Murray, MD, PhD
Alex Rai, PhD
Teresita Redondo, MD, FCAP
Lesley Souter, PhD
Brooke Billman, MLIS
Christina B. Ventura, MPH, MT(ASCP)